DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Phase 2

Recruiting

Conditions: Envafolimab
Capecitabine
Pancreatic Cancer
Radiotherapy

Interventions: Radiation: concurrent radiotherapy with envafolimab and capecitabine

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-19

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT06202014

Locations: 🇨🇳
Bo Chen, Beijing, Beijing, China

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab

First Posted Date: 2024-01-11

Last Posted Date: 2024-04-02

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 70

Registration Number: NCT06202001

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Phase 2

Not yet recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Golidocitinib
Drug: Sintilimab
Drug: platinum doublet chemotherapy

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT06198907

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer, Familial Male
Immune Checkpoint Inhibitor
CDK4/6 Inhibitor
Radiotherapy; Complications
Chemotherapeutic Toxicity
Trastuzumab
Pertuzumab
PARP Inhibitor

Interventions: Radiation: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)

First Posted Date: 2024-01-09

Last Posted Date: 2024-08-21

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 148

Registration Number: NCT06197581

Locations: 🇨🇳
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Not Applicable

Recruiting

Conditions: Thymus Neoplasms

Interventions: Radiation: Adjuvant Hypofractionation Radiotherapy

First Posted Date: 2024-01-03

Last Posted Date: 2024-02-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT06189183

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2

Not yet recruiting

Conditions: Disitamab Vedotin
ERBB2 Mutation-Related Tumors
Non Small Cell Lung Cancer
ERBB2 Gene Duplication

Interventions: Drug: Disitamab Vedotin
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Drug: pyrotinib

First Posted Date: 2023-12-29

Last Posted Date: 2023-12-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 108

Registration Number: NCT06185400

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Anti-PD-1 monoclonal antibody
Other: Postoperative CCRT

First Posted Date: 2023-12-14

Last Posted Date: 2023-12-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 173

Registration Number: NCT06170710

Locations: 🇨🇳
National Cancer Cencer/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Camrelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Lobaplatin
Drug: Nedaplatin
Radiation: Radiotherapy

First Posted Date: 2023-12-14

Last Posted Date: 2023-12-20

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 46

Registration Number: NCT06170697

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

Interventions: Drug: Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy

First Posted Date: 2023-12-11

Last Posted Date: 2024-02-02

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT06163729

Locations: 🇨🇳
Shugeng Gao, Beijing, Beijing, China

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Mitoxantrone hydrochloride liposome
Drug: Capecitabine

First Posted Date: 2023-12-05

Last Posted Date: 2023-12-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 24

Registration Number: NCT06156761

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy